GlioDx Blood platelet based monitoring and treatment optimisation for glioblas...
GlioDx Blood platelet based monitoring and treatment optimisation for glioblastoma patients
Glioblastoma (GBM) is a devastating primary brain cancer which affects about 230.000 people annually. The choice for treatment depends on the subtype of GBM. An accurate detection of tumour subtype is therefore essential for a per...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2011-23870
MEJORA DE LOS PROTOCOLOS PARA DIAGNOSTICO Y SEGUIMIENTO DE R...
327K€
Cerrado
PID2020-113058GB-I00
LEVELING UP IN GB THERAPY MONITORING: TOWARDS A UNIVERSAL BI...
121K€
Cerrado
TIN2013-43457-R
CARACTERIZACION DE FIRMAS BIOLOGICAS DE GLIOBLASTOMAS MEDIAN...
80K€
Cerrado
GlyCan
Innovative Glycan based analysis for Cancer diagnostics
71K€
Cerrado
CANOMICS
Multicentre discovery of breast cancer biomarkers
86K€
Cerrado
DPI2016-80054-R
BIOMARCADORES DINAMICOS BASADOS EN FIRMAS TISULARES MULTIPAR...
119K€
Cerrado
Información proyecto GlioDx
Duración del proyecto: 19 meses
Fecha Inicio: 2016-07-22
Fecha Fin: 2018-02-28
Líder del proyecto
STICHTING AMSTERDAM UMC
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Glioblastoma (GBM) is a devastating primary brain cancer which affects about 230.000 people annually. The choice for treatment depends on the subtype of GBM. An accurate detection of tumour subtype is therefore essential for a personalised targeted treatment. Diagnosis, classification and treatment monitoring occurs currently by radiology and repeated invasive biopsies. There is a need for non-invasive, actionable biomarkers for early-stage diagnosis and disease monitoring.
During our ERC research, we discovered that mRNA sequenced from tumour-educated platelets enables for pan-cancer, multiclass cancer and companion diagnostics. We were able to distinguish between primary and metastasised tumours in the brain and also establish the molecular subtype of the tumour. These findings provide strong support for using tumour-educated platelets as a biomarker for early stratification, diagnosis and prognosis for personalised GBM treatment.
As a proof-of-concept of our innovative diagnostic tests, we will validate the proprietary algorithms underlying these tests specifically in GBM patients. To achieve this, we focus on the differentiation of glioblastoma subtype based on the platelet mRNA profile. In addition we will validate treatment monitoring and response prediction to an EGFR targeted drug in GBM patients.
GlioDx will also assess the feasibility to commercialise the technology. The team has developed several business and IP models which need to be assessed thoroughly through in-depth market research and business planning activities. The results need to be consolidated into a strong business plan that will be presented to investors and strategic investors.